🫀 Hepatic Dose Adjustment Key Points
Adjustment and avoidance points for common drugs in hepatic impairment, organised by drug class with Child-Pugh framing. Browser-side reference.
Hepatic Dose Adjustment Key Points
View
When to use
Bedside reminder of which drugs to reduce or avoid in liver disease and what to monitor. Not exhaustive — follow the product label.
How it works
No quantitative hepatic index like eGFR; grade by Child-Pugh (A/B/C) and reduce hepatically-cleared drugs in B/C.
Key points
- Avoid hepatotoxins; monitor LFTs, bilirubin, INR and for encephalopathy.
- Prefer oxazepam/lorazepam over long-acting benzodiazepines.
- Statins are contraindicated in active liver disease; warfarin needs close INR monitoring.
- Watch for hidden acetaminophen in combination products.
References
Decision support for licensed clinicians only; not a substitute for clinical judgement, diagnosis or local protocols.